114
Registered trials
51
Recruiting
50
Completed trials
69
Sponsors
25
Countries
Phase III:
41
Phase II/III:
18
Phase II:
36
Phase I/II:
8
Phase III/IV:
1
Phase IV:
3
Phase I (Other):
2
Phase I (FiH):
5
Oversight events:
2 serious breaches
8 temporary halts
3 urgent safety measures
2 unexpected events
1 corrective measure
across 9 trials
View oversight register →
Indications tested
Non-small cell lung cancer
8
Cholangiocarcinoma
6
Diffuse large B-cell lymphoma
3
Non-small cell lung cancer stage IV
2
Bladder cancer
2
Head and neck cancer
2
Transitional cell carcinoma
2
Ewing's sarcoma
1
Extra-osseous Ewing's sarcoma recurrent
1
Glioblastoma
1
Hepatocellular carcinoma
1
Non-Hodgkin's lymphoma unspecified histology aggressive recurrent
1
Sponsors using this IMP
AstraZeneca AB
14
Merck Sharp & Dohme LLC
7
Bristol-Myers Squibb Services Unlimited Company
4
AbbVie Deutschland GmbH & Co. KG
3
F. Hoffmann-La Roche AG
3
Fondation Franc.Cancerologie Digestive
3
Gilead Sciences Inc.
3
Seagen Inc.
3
Unicancer
3
Asociacion Europea Y Latinoamericana SELNET Para La Investigacion En Sarcomas
2
Bicycletx Limited
2
Centre Hospitalier Universitaire Rouen
2
All trials — page 5
114 totalShowing 97–114 of 114 trials